Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TA-1502
- Development stage
- Unknown
- Lead developer
- Zedman
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
TA-1502 is a small molecule aryl hydrocarbon receptor (AhR) modulator being developed by Zedman Biopharma for the topical treatment of seborrheic dermatitis. AhR is a ligand-dependent transcription factor that plays a crucial role in skin barrier function and immune response. By modulating AhR activity, TA-1502 aims to reduce inflammation and restore skin homeostasis. The drug is currently in Phase 2 clinical development and is formulated as a topical spray to facilitate application on hair-bearing areas typically affected by seborrheic dermatitis.
- Other names
- TA-1502TA1502TA 1502TA-1502 喷雾剂TA-1502 SprayTA1502 SprayTA 1502 Spray
02
Targets
AHR (Aryl hydrocarbon receptor)
Beyond the preview
Go deeper on TA-1502.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TA-1502.